Trial Profile

A Phase 2, Open-Label Study of LCAR-B38M CAR-T Cells, a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against BCMA in Chinese Subjects With Relapsed or Refractory Multiple Myeloma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 20 Dec 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ciltacabtagene autoleucel (Primary)
Indications Multiple myeloma
Focus Registrational; Therapeutic Use
Acronyms CARTIFAN-1
Sponsors Nanjing Legend Biotech

Most Recent Events

17 Dec 2025 Status changed from active, no longer recruiting to discontinued due to a strategic realignment of the sponsor's business plan, not related to safety, efficacy, or data integrity concerns.
03 Sep 2025 Planned End Date changed from 16 Feb 2026 to 20 Oct 2025.
25 Jun 2025 Planned number of patients changed from 130 to 123.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com